Compliance Rate

Compliance Rate 50.0%
Compliant submissions 1
Incompliant submissions 1
Total trials 2

My Organizations' Clinical Trials

Showing 1825 of 3499 entries
View as:

Thalidomide in Treating Patients With Myelofibrosis

Phase: N/A Priority: Normal
NCT ID: NCT00015821 Org: User:
Start: 05/31/00 End: - Due: -

17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy

Phase: N/A Priority: Normal
NCT ID: NCT00118092 Org: User:
Start: 01/31/05 End: 02/29/08 Due: 02/28/09

Sorafenib in Treating Patients With Recurrent Non-Hodgkin's Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00278382 Org: User:
Start: 10/31/05 End: - Due: -

Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery

Phase: N/A Priority: Normal
NCT ID: NCT00381641 Org: User:
Start: 08/29/06 End: 12/10/24 Due: 12/10/25

Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT03813147 Org: User:
Start: 05/17/19 End: 12/31/23 Due: 12/31/24

Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT02581930 Org: User:
Start: 08/17/16 End: 03/17/26 Due: 03/17/27

Total Body Irradiation for Bone Marrow Transplants: Collaborative Efforts

Phase: N/A Priority: Normal
NCT ID: NCT00026858 Org: User:
Start: 10/31/94 End: 11/30/02 Due: 11/30/03

3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT00077181 Org: User:
Start: 01/31/04 End: - Due: -

GTI-2040, Oxaliplatin, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer or Other Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00084643 Org: User:
Start: 05/31/04 End: - Due: -

Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01540565 Org: User:
Start: 04/09/12 End: 01/27/18 Due: 01/27/19

A Phase I/II Study of Paclitaxel, Carboplatin and YM155 (Survivin Suppressor) in Subjects With Solid Tumors (Phase I) and Advanced Non-Small Cell Lung Carcinoma (Phase II)

Phase: N/A Priority: Normal
NCT ID: NCT01100931 Org: User:
Start: 02/28/10 End: 12/31/12 Due: 12/31/13

Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02059265 Org: User:
Start: 02/14/14 End: 06/26/23 Due: 06/26/24

Interferon Alfa Plus Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00015912 Org: User:
Start: 07/31/01 End: - Due: -

Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03367741 Org: User:
Start: 04/16/18 End: 12/31/25 Due: 12/31/26

Machine Learning to Analyze Facial Imaging, Voice and Spoken Language for the Capture and Classification of Cancer/Tumor Pain

Phase: N/A Priority: Normal
NCT ID: NCT04442425 Org: User:
Start: 10/27/20 End: 03/27/24 Due: 03/27/25

Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm

Phase: N/A Priority: Normal
NCT ID: NCT05600894 Org: User:
Start: 06/27/23 End: 08/31/25 Due: 08/31/26

A Phase II Trial of Cetuximab and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00409565 Org: User:
Start: 09/30/06 End: 02/29/12 Due: 02/28/13

Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00363272 Org: User:
Start: 06/30/06 End: - Due: -

Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis

Phase: N/A Priority: Normal
NCT ID: NCT04557969 Org: User:
Start: 12/18/20 End: 12/30/40 Due: 12/30/41

Saracatinib in Treating Patients With Relapsed or Refractory Thymoma or Thymic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00718809 Org: User:
Start: 06/30/08 End: 10/31/13 Due: 10/31/14

Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers

Phase: N/A Priority: Normal
NCT ID: NCT04491955 Org: User:
Start: 09/22/20 End: 08/16/24 Due: 08/16/25

Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT06169215 Org: User:
Start: 07/23/24 End: 09/30/26 Due: 09/30/27

Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05836584 Org: User:
Start: 12/06/23 End: 10/31/27 Due: 10/31/28

Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02079740 Org: User:
Start: 03/26/14 End: 03/06/26 Due: 03/06/27

Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

Phase: N/A Priority: Normal
NCT ID: NCT02978625 Org: User:
Start: 09/27/17 End: 09/01/25 Due: 09/01/26